Vertex Pharmaceuticals announces updated data from RUBY-3 study of povetacicept

Vertex Pharmaceuticals (VRTX) announced updated data for povetacicept in IgA nephropathy and primary membranous nephropathy from the ongoing RUBY-3 trial at the American Society of Nephrology, ASN, Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF and APRIL cytokines. Key points: 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases ; Vertex on track to initiate rolling submission of Biologics License Application for potential accelerated approval to the U.S. Food and Drug Administration this year; full enrollment completed for Phase 3 RAINIER trial in IgA nephropathy; Povetacicept in primary membranous nephropathy granted Fast Track Designation by the U.S. Food and Drug Administration and Phase 2/3 pivotal trial initiated.